Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- R. Herbst, Jean-Charles Soria, +19 authors F. S. Hodi
- Biology, Medicine
- Nature
- 27 November 2014
The development of human cancer is a multistep process characterized by the accumulation of genetic and epigenetic alterations that drive or reflect tumour progression. These changes distinguish… Expand
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
BACKGROUND
The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti-PD-1 antibody lambrolizumab… Expand
High-throughput oncogene mutation profiling in human cancer
- R. Thomas, Alissa C. Baker, +50 authors L. Garraway
- Biology, Medicine
- Nature Genetics
- 1 March 2007
Systematic efforts are underway to decipher the genetic changes associated with tumor initiation and progression. However, widespread clinical application of this information is hampered by an… Expand
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
- S. Topalian, M. Sznol, +18 authors F. S. Hodi
- Medicine
- Journal of clinical oncology : official journal…
- 1 April 2014
PURPOSE
Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of immune memory. PD-1 blockade can… Expand
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- D. Frederick, A. Piris, +18 authors J. Wargo
- Biology, Medicine
- Clinical Cancer Research
- 10 January 2013
Purpose: To evaluate the effects of BRAF inhibition on the tumor microenvironment in patients with metastatic melanoma. Experimental Design: Thirty-five biopsies were collected from 16 patients with… Expand
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
- D. Schadendorf, F. S. Hodi, +7 authors J. Wolchok
- Medicine
- Journal of clinical oncology : official journal…
- 9 February 2015
PURPOSE
To provide a more precise estimate of long-term survival observed for ipilimumab-treated patients with advanced melanoma, we performed a pooled analysis of overall survival (OS) data from… Expand
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- C. Robert, A. Ribas, J. Wolchok, F. S. Hodi, A. Daud
- Medicine
- The Lancet
- 20 September 2014
BACKGROUND
The anti-programmed-death-receptor-1 (PD-1) antibody pembrolizumab has shown potent antitumour activity at different doses and schedules in patients with melanoma. We compared the efficacy… Expand
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
- K. Margolin, M. Ernstoff, +12 authors F. S. Hodi
- Medicine
- The Lancet. Oncology
- 1 May 2012
BACKGROUND
Brain metastases commonly develop in patients with melanoma and are a frequent cause of death of patients with this disease. Ipilimumab improves survival in patients with advanced… Expand
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Here we report a phase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on cytotoxic T cell infiltration and therapeutic efficacy of the anti-PD-1 antibody… Expand
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
- Brian C Miller, D. Sen, +24 authors W. Haining
- Biology, Medicine
- Nature Immunology
- 18 February 2019
T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) reinvigorates T cells… Expand